AlloVir

Allogeneic, Off-The-Shelf, Multi-Virus Specific T-Cell Immunotherapies

Also Clin3 adenovirus, Clin3 multi-virus prevention, Clin1b/Clin2 kidney transplant BK virus, Clin0 organ transplant virus protection; ALVR106 Clin1b/Clin2 multiple viral infections, Clin0 multiple viral infections; ALVR107 Clin0 HBV

AlloVir focuses on designing treatments for viral infections in immunocompromised patients with limited or no conventional treatment options. Their platform utilizes virus-specific T cells (VSTs) from healthy donors to confer immunity to patients with T cell deficiencies. AlloVir products are available off the shelf, with 11 potentially devastating viruses currently targeted for treatment with VST technology. AlloVir creates VSTs by identifying viral antigens that produce robust T cell responses. Donors are screened and PBMCs are harvested and stimulated with peptide libraries targeting viral antigens. Promising candidates are selected and expanded while ensuring polyclonal populations. These virus-specific T cells are then cryopreserved and available off the shelf.

Jobs: